Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

GoPro, Krispy Kreme, and Kohl’s surge as meme stock mania returns. Retail traders drive volatility in a high-liquidity, ...

Wall Street's biggest bull sees tech and AI driving an 11% stock gain, fueled by strong fundamentals, M&A activity, and ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over ...

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

A retirement-ready portfolio consists of reliable, income-generating stocks that quietly compound over time. Realty Income (O ...

As different stocks rise and fall, so do dividend yields, creating a shifting landscape of opportunities for income-oriented investors. Increases in dividend per share (DPS) greatly allow companies to ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.

PBF Energy Inc. (NYSE: PBF) is one of the 10 Energy Stocks with Insider Buying in 2025. Despite the successful completion of ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...